Overall, our studies provide in vitro and in vivo support for single-agent TNO155 treatment in neuroblastoma and demonstrate the efficacy and tolerability of TNO155 combinations with ALK-TKIs in several ALK-mutant neuroblastoma models. Here, ALK is linked to neuroblastoma.